Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Decreases By 49.7%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 28,500 shares, a decrease of 49.7% from the May 31st total of 56,700 shares. Based on an average daily volume of 152,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.2% of the shares of the company are short sold.

Virpax Pharmaceuticals Price Performance

Virpax Pharmaceuticals stock remained flat at $0.52 during mid-day trading on Friday. 39,066 shares of the company’s stock were exchanged, compared to its average volume of 255,056. The firm’s fifty day moving average is $1.35 and its 200 day moving average is $2.78. Virpax Pharmaceuticals has a 1 year low of $0.46 and a 1 year high of $11.70.

Virpax Pharmaceuticals (NASDAQ:VRPX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($2.75) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, May 22nd.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.